Journal of Medicinal Chemistry p. 3839 - 3853 (2011)
Update date:2022-08-04
Topics:
Zhao, Huiping
Donnelly, Alison C.
Kusuma, Bhaskar R.
Brandt, Gary E. L.
Brown, Douglas
Rajewski, Roger A.
Vielhauer, George
Holzbeierlein, Jeffrey
Cohen, Mark S.
Blagg, Brian S. J.
Development of the DNA gyrase inhibitor, novobiocin, into a selective Hsp90 inhibitor was accomplished through structural modifications to the amide side chain, coumarin ring, and sugar moiety. These species exhibit ?700- fold improved anti-proliferative activity versus the natural product as evaluated by cellular efficacies against breast, colon, prostate, lung, and other cancer cell lines. Utilization of structure- activity relationships established for three novobiocin synthons produced optimized scaffolds, which manifest midnanomolar activity against a panel of cancer cell lines and serve as lead compounds that manifest their activities through Hsp90 inhibition.
View MoreContact:+86-574-89075960
Address:#100 Xiang Yun Road, New High tech area, Ningbo, China
Shanghai Pinewood Fine Chemical Co., Ltd.
website:http://www.pinewoodchem.com
Contact:0086-21-62417129,62414096
Address:Suite B, 27F, No.2, Lane 600, Tianshan Road, Shanghai
Hebei Think-Do Environment Co., Ltd
website:http://www.thinkdo-environment.com
Contact:0311-86510809
Address:No 6, Shilian Middle Street, Circular Chemical Industry Park
Tianjin Pharmacn Medical Technology Co.,Ltd.
Contact:86-22-60122566ext.866(English),23359620
Address:Green Industrial Base, 6 Haitaifazhan Sixth Rd., Huayuan Industrial Area, Tianjin, 300384, China
Xinjiang Zhongtai Chemical Co., Ltd.
Contact:+86-991-8788172
Address:NO.78 XISHAN RD.URUMQI,CHINA
Doi:10.1016/S0040-4020(01)87764-4
(1990)Doi:10.1002/jhet.5570340235
(1997)Doi:10.1002/anie.201007727
(2011)Doi:10.1016/j.bmc.2011.04.009
(2011)Doi:10.1002/chem.201003711
(2011)Doi:10.1021/jo00001a030
(1991)